Poly Medicure Limited · NSE:POLYMED
Poly Medicure — Shareholder Meeting (September 2024)
25 slides from Poly Medicure's shareholder meeting presentation, September 2024
Slide 1: Welcome to the 29th Annual General Meeting
Welcome to the 29 Annual th General Meeting Poly Medicure Ltd. September 2024 Confidential I Slide 1
Slide 2: Forward Looking Statement
Forward Looking Statement Disclaimer This presentation has been prepared for general information purposes in respect of Poly Medicure Limited (“Company”) together with any subsidiary, associate or joint venture, as applicable (together, with the Company, the “Group”) only, without regard to any spec
Slide 3: Polymed at a Glance
We have a global presence in the medical devices space Polymed at a Glance 12 12 Manufacturing Plants Specialities Across 4 countries 125+ Countries 200+ Medical Devices 4000+ Employee Base 400+ Sales Associates 325+ Patents Granted 1.5 Billion+ Devices Manufacturing Capacity 40+ applications pendin
Slide 4: Navigating Our Journey: Polymed's Path of Milestones and Triumphs
Navigating Our Journey Polymed's Path of Milestones and Triumphs 1997 2004 2009 2014 2018 2020 2023 2025 Commencement Faridabad China Plant New Plant Renal Care New Plant in 4 New Plants Gamma of Manufacturing Plant 2 -Poly Medicure (Dialysis) IMT Faridabad Expansion in Sterilization SEZ Jaipur Fari
Slide 5: Navigating the Path
Navigating the Path Building Tomorrow’s Healthcare Solutions Started In 2028 1997 2002-09 2011-19 2020-24 2025 - 27 & beyond Commencement Product and facility New R&D Center, of Manufacturing expansion Acq of Plan 1 Health, Operation New Manufacturing › Launched › Prioritize the › Through a Plants d
Slide 6: Polymed's Ecosystem
Polymed’s Ecosystem Clinical Support Distribution Network Sales & Marketing Product Concept Product Product Design Manufacturing Rapid Prototyping Product Packaging Regulatory Sterilization Compliance Tool Design Tool Manufacturing Confidential I Slide 19
Slide 7: Comprehensive Integration: Our Solutions Enhance Care Across the Hospital Spectrum
Comprehensive Integration Our Solutions Enhance Care Across the Hospital Spectrum IPD ICU Blood Bank Emergency Dialysis Unit Operation Theatre Chemotherapy Pathology Lab Day Unit Specialty Treatment Units Cath Lab Gaestrontology, Urology Confidential I Slide 5
Slide 8: Our Innovations Deliver Vital Care to Key Clinical Specialties
Our Innovations Deliver Vital Care to Key Clinical Specialties Cardiology Anaesthesia & Respiratory Care Transfusion System Oncology Vascular Access Infusion Therapy Gastroenterology Diagnostics Urology Dialysis & Renal Care Surgery & Wound Drainage Critical Care Confidential I Slide 6
Slide 9: Value Creation through Innovation and Streamlined Operational Models
Value Creation through Innovation and Streamlined Operational Models Template GROW INNOVATE SCALE ▪ Foster sustainable revenue expansion, Striving for Margin ▪ Strategic Investments in ▪ Enhancing Manufacturing Growth High-Growth Areas - Capacities to global scale. ▪ Build direct presence in key Car
Slide 10: Mastering Manufacturing
Mastering Manufacturing Striving Towards Operational Excellence 350+ Moulding Machines and 1500+ Moulds & Dies 200+ Automatic Assembly Machines 100+ Robots employed in our manufacturing processes Confidential I Slide 22
Slide 11: Polymed's Manufacturing Footprint
Polymed's Manufacturing Footprint 12 Facilities across 3 continents 117,Faridabad, India IMT 1,Faridabad, India SEZ 2, Jaipur, India Laiyang-qingdao, 104-105,Faridabad Amaro, Italy Haridwar Plant, India IMT 2, Faridabad 115-116, Faridabad SEZ 1 Jaipur, India R & D Centre, India Assuit, Egypt China P
Slide 12: Diving into Our Product Portfolio
Diving into Our Product Portfolio Vascular Access Mini Mid Peripherally Inserted Peripherally inserted Central Venous Safety Introducer Safety Winged IV Cannula Arterial Catheter Catheters Lines - OTN Central Catheter Venous Catheters Infusion Set Needle Infusion Therapy Extension Lines with Infusio
Slide 13: Cardiology, Surgery and Wound, and Other Products
Cardiology Diagnostic Catheter PTCA Balloon PTCA Balloon Hydrophilic Guidewire PTFE Coated Guidewire Dilation Catheter SC Dilation Catheter NC Guiding Catheter Surgery and Wound Closed Wound Drainage Suction Unit Closed Wound High Pressure Redon Under Water Thoracic Yankauer Yankauer Suction Unit wi
Slide 14: Creating Value for Stakeholders
Creating Value for Stakeholders MARKET CAP IN ₹ CRS 25000 23684.26 20000 15000 14052 10000 5000 0 Market Cap 31-08-2023 31-08-2024 Date Market Cap (in ₹ crs) 31-08-2023 14,052 31-08.2024 23,684 Confidential I Slide 16
Slide 15: Our Strength: Consistent all-round growth
Our Strength: Consistent all-round growth ₹ ₹ ₹ REVENUE (₹ Crs) EBIDTA (₹ Crs) PBT (₹ Crs) PAT (₹ Crs) 400.00 1600.00 500.00 344.27 300.00 1375.79 350.00 258.26 1400.00 419.50 300.00 250.00 1200.00 1115.23 400.00 237.49 179.28 923.06 303.50 250.00 200.00 1000.00 300.00 195.24 146.51 253.45 200.00 15
Slide 16: Financial Performance Comparison
Financial Performance Comparison (Standalone & Consolidated) (₹ in lacs except per share data) Standalone Consolidated Quarter Ended Quarter Ended 30.06.2024 31.03.2024 30.06.2023 30.06.2024 31.03.2024 30.06.2023 (Unaudited) (Audited) (Unaudited) (Unaudited) (Audited) (Unaudited) Total income from 3
Slide 17: Ratio's (in %)
Ratio’s (in %) ROCE ROE 25 20 18.91 22.91 18 17.26 20.94 20 16 14.51 17.48 13.56 14 15 14.05 12 10 10 8 6 5 4 2 0 0 FY 22 FY 23 FY 24 Q1 25 FY 22 FY 23 FY 24 Q1 25
Slide 18: Revenue Mix
REVENUE MIX Domestic/Export 120.00% 100.00% 31.96% 32.40% 29.17% 80.00% 60.00% 40.00% 68.04% 67.60% 70.83% 20.00% 0.00% FY 23-24 Q1 23-24 Q1 24-25 Export Domestic Growth Q Sales FY 23-24 % Q1-23-24 % Q1-24-25 % over Q Exports 897.29 68.04% 206.56 67.6% 262.76 70.83% 27.21% Domestic 409.95 31.96% 99.
Slide 19: Qualified Institutional Placement (QIP)
Qualified Institutional Placement (QIP) Institutional Demand ₹ 8,665 crs Allotment Total Fund Raise At Rs.1880/ share 1,000 crs (in INR) 60 new investors onboard (22.08.24) No. of meetings/ Roadshows 75 Confidential I Slide 11
Slide 20: QIP New Stakeholders
QIP New Stakeholders Shareholding - Adding Institutional Shareholders 70.00 66.03 62.56 60.00 50.00 40.00 30.00 23.58 19.26 20.00 14.71 13.86 10.00 0.00 Promoters Institutional Investors Indian public Pre QIP Post QIP 22.08.2024 Shareholder Category in % Pre QIP Post QIP 22nd August Promoters 66.03
Slide 21: Expansion
Expansion An outlay of ₹500 crs over next 2 years for 3 manufacturing facilities at Haryana, Uttarakhand and Rajasthan Exploring Technology Acquisition in the area of Cardiology, Renal and Critical Care Confidential I Slide 15
Slide 22: Way Forward
Way Forward Research & Development ▪ Targeted R&D investments towards transformative therapeutic areas, aiming to pioneer breakthrough innovations Emphasizing Inorganic Growth ▪ Integration of AI and IoT technologies to enhance efficiency & precision Strategic Alliances to foster synergies and expan
Slide 23: Recent Accolades
Recent Accolades “Export Excellence Award” Economic Times by PLEXCONCIL Best Healthcare Brands 2024 Largest Exporter of medical disposables from India Year 2021-22 & 2022-23 Confidential I Slide 20
Slide 24: Sustainable Development
Towards our Commitment to a Sustainable World 6.14% HSD Saving 26 Pits for 30 KL Rain Harvesting; by convert Steam Boilers with 90% of the wastewater is PNG & minimize HT Line faults being reused FUEL SAVING WATER RECYCLING Power consumption per Produced Solar Energy production unit remains steady 1
Slide 25: Thank You
Poly Medicure Limited Registered Office: Thank You 232 B, 3rd Floor, Okhla Industrial Estate, Phase III, New Delhi-110020, India Tel:- 91-11-33550700, 47317000, 26321838/99 For any general queries, Reach us at: info@polymedicure.com Visit: www.polymedicure.com Confidential I Slide 27